338 related articles for article (PubMed ID: 34351000)
21. Specialized Versus Generic Allied Health Therapy and the Risk of Parkinson's Disease Complications.
Talebi AH; Ypinga JHL; De Vries NM; Nonnekes J; Munneke M; Bloem BR; Heskes T; Ben-Shlomo Y; Darweesh SKL
Mov Disord; 2023 Feb; 38(2):223-231. PubMed ID: 36424819
[TBL] [Abstract][Full Text] [Related]
22. Safety of Plasma Infusions in Parkinson's Disease.
Parker JE; Martinez A; Deutsch GK; Prabhakar V; Lising M; Kapphahn KI; Anidi CM; Neuville R; Coburn M; Shah N; Bronte-Stewart HM
Mov Disord; 2020 Nov; 35(11):1905-1913. PubMed ID: 32633860
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of the Parkinson's KinetiGraph and clinical assessment in the management of Parkinson's disease.
Chaudhuri KR; Hand A; Obam F; Belsey J
J Med Econ; 2022; 25(1):774-782. PubMed ID: 35593687
[TBL] [Abstract][Full Text] [Related]
24. The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States.
Martinez-Martin P; Macaulay D; Jalundhwala YJ; Mu F; Ohashi E; Marshall T; Sail K
Mov Disord; 2019 Feb; 34(2):236-245. PubMed ID: 30589953
[TBL] [Abstract][Full Text] [Related]
25. The mortality rate of Parkinson's disease and related comorbidities: a nationwide population-based matched cohort study in Korea.
Yoon SY; Shin J; Kim YW; Chang JS; Won Kim H
Age Ageing; 2021 Jun; 50(4):1182-1188. PubMed ID: 33219665
[TBL] [Abstract][Full Text] [Related]
26. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
Williams-Gray CH; Wijeyekoon R; Yarnall AJ; Lawson RA; Breen DP; Evans JR; Cummins GA; Duncan GW; Khoo TK; Burn DJ; Barker RA;
Mov Disord; 2016 Jul; 31(7):995-1003. PubMed ID: 26999434
[TBL] [Abstract][Full Text] [Related]
27. Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
van den Heuvel L; Evers LJW; Meinders MJ; Post B; Stiggelbout AM; Heskes TM; Bloem BR; Krijthe JH
Mov Disord; 2021 Feb; 36(2):407-414. PubMed ID: 33107639
[TBL] [Abstract][Full Text] [Related]
28. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.
Becker C; Jick SS; Meier CR
Drug Saf; 2008; 31(5):399-407. PubMed ID: 18422380
[TBL] [Abstract][Full Text] [Related]
29. Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression.
Senkevich K; Alipour P; Chernyavskaya E; Yu E; Noyce AJ; Gan-Or Z
Mov Disord; 2023 Jul; 38(7):1350-1355. PubMed ID: 37148456
[TBL] [Abstract][Full Text] [Related]
30. Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
Scherbaum R; Kwon EH; Richter D; Bartig D; Gold R; Krogias C; Tönges L
Mov Disord; 2021 May; 36(5):1049-1057. PubMed ID: 33942924
[TBL] [Abstract][Full Text] [Related]
31. Twenty-year sociodemographic trends in lung cancer in non-smokers: A UK-based cohort study of 3.7 million people.
Rait G; Horsfall L
Cancer Epidemiol; 2020 Aug; 67():101771. PubMed ID: 32659727
[TBL] [Abstract][Full Text] [Related]
32. Identifying Protective Drugs for Parkinson's Disease in Health-Care Databases Using Machine Learning.
Courtois É; Nguyen TTH; Fournier A; Carcaillon-Bentata L; Moutengou É; Escolano S; Tubert-Bitter P; Elbaz A; Thiébaut ACM; Ahmed I
Mov Disord; 2022 Dec; 37(12):2376-2385. PubMed ID: 36054665
[TBL] [Abstract][Full Text] [Related]
33. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Brauer R; Wei L; Ma T; Athauda D; Girges C; Vijiaratnam N; Auld G; Whittlesea C; Wong I; Foltynie T
Brain; 2020 Oct; 143(10):3067-3076. PubMed ID: 33011770
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.
Simuni T; Siderowf A; Lasch S; Coffey CS; Caspell-Garcia C; Jennings D; Tanner CM; Trojanowski JQ; Shaw LM; Seibyl J; Schuff N; Singleton A; Kieburtz K; Toga AW; Mollenhauer B; Galasko D; Chahine LM; Weintraub D; Foroud T; Tosun D; Poston K; Arnedo V; Frasier M; Sherer T; Chowdhury S; Marek K;
Mov Disord; 2018 May; 33(5):771-782. PubMed ID: 29572948
[TBL] [Abstract][Full Text] [Related]
35. Occupational stress and risk for Parkinson's disease: A nationwide cohort study.
Sieurin J; Andel R; Tillander A; Valdes EG; Pedersen NL; Wirdefeldt K
Mov Disord; 2018 Sep; 33(9):1456-1464. PubMed ID: 30145813
[TBL] [Abstract][Full Text] [Related]
36. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
[TBL] [Abstract][Full Text] [Related]
37. Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study.
Yin W; Löf M; Pedersen NL; Sandin S; Fang F
Mov Disord; 2021 Jan; 36(1):255-260. PubMed ID: 33078857
[TBL] [Abstract][Full Text] [Related]
38. Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease.
Paul KC; Schulz J; Bronstein JM; Lill CM; Ritz BR
JAMA Neurol; 2018 Mar; 75(3):360-366. PubMed ID: 29340614
[TBL] [Abstract][Full Text] [Related]
39. Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
Chohan H; Senkevich K; Patel RK; Bestwick JP; Jacobs BM; Bandres Ciga S; Gan-Or Z; Noyce AJ
Mov Disord; 2021 Jun; 36(6):1420-1429. PubMed ID: 33682937
[TBL] [Abstract][Full Text] [Related]
40. Risk of incident depression in patients with Parkinson disease in the UK.
Becker C; Brobert GP; Johansson S; Jick SS; Meier CR
Eur J Neurol; 2011 Mar; 18(3):448-53. PubMed ID: 20722714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
